Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · November 23, 2022

Addition of Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Newly Diagnosed Transplantation-Eligible Multiple Myeloma

The Lancet Haematology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Lancet Haematol 2022 Nov 01;9(11)e810-e821, H Goldschmidt, EK Mai, U Bertsch, R Fenk, E Nievergall, D Tichy, B Besemer, J Dürig, R Schroers, I von Metzler, M Hänel, C Mann, AM Asemissen, B Heilmeier, N Weinhold, S Huhn, K Kriegsmann, SP Luntz, TAW Holderried, K Trautmann-Grill, D Gezer, M Klaiber-Hakimi, M Müller, C Khandanpour, W Knauf, C Scheid, M Munder, T Geer, H Riesenberg, J Thomalla, M Hoffmann, MS Raab, HJ Salwender, KC Weisel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading